Advertisement
Advertisement
SLN
Silence Therapeutics Plc - ADR
13.58
USDSponsored
-1.14
-7.74%
Aug 12, 16:00 UTC -4
Closed
Pre-Market
14.23
+0.65
+4.82%
SLN Earnings Reports
Positive Surprise Ratio
No Data Available for SLN
0%
Next Report
Date of Next Report
Nov 05, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/--
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q3 25 (Revenue/ EPS)
--
/--
Silence Therapeutics Plc - ADR earnings per share and revenue
On Aug 10, 2026, SLN reported earnings of -0.26 USD per share (EPS) for Q2 26, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference. The market reacted with a +29.12% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Harrow, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.34
Surprise
-85.19%
Altimmune, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.12
Surprise
+14.22%
Aquestive Therapeutics, Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.10
Actual
-$0.18
Surprise
-70.78%
Journey Medical Corporation Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.01
Surprise
+56.33%
Heron Therapeutics, Inc.
Report Date
Aug 10, 2026 For Q2 26
Estimate
$0.01
Actual
-$0.03
Surprise
-394.12%
PolyPid Ltd. Ordinary Shares
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.35
Surprise
+9.28%
Talphera, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.06
Actual
-$0.06
Surprise
+11.76%
Oruka Therapeutics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.52
Actual
-$0.55
Surprise
-4.62%
Vyome Holdings, Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-$0.19
Actual
-$0.10
Surprise
+48.40%
CDT Equity Inc. Common Stock
Report Date
Aug 12, 2026 For Q2 26
Estimate
-Actual
-$8.71
Surprise
-
FAQ
What were Silence Therapeutics Plc - ADR's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Silence Therapeutics Plc - ADR reported EPS of -$0.26, missing estimates by --, and revenue of $0.00, -- -- expectations.
How did the market react to Silence Therapeutics Plc - ADR's Q2 2026 earnings?
The stock price moved up 29.12%, changed from $11.95 before the earnings release to $15.43 the day after.
When is Silence Therapeutics Plc - ADR expected to report next?
The next earning report is scheduled for Nov 05, 2026.
What are the forecasts for Silence Therapeutics Plc - ADR's next earnings report?
Based on --
analysts, Silence Therapeutics Plc - ADR is expected to report EPS of -- and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement